In conclusion, we found a high rate of COVID-19 vaccination among uro-oncology patients receiving systemic targeted therapy with tyrosine kinase receptor inhibitors (TKIs) for mRCC and systemic therapy with androgen receptor target agents (ARTAs) for mCRPC. Here, AR is linked to COVID-19.